Want to see HK:3347 full AI Analyst Report?
Top Page
Hangzhou Tigermed Consulting Co., Ltd. Class H
(3347)
Select Model
Select Model
Rating:55Neutral
Price Target:
HK$39.00
â–Ľ(-27.78% Downside)
Action:Reiterated
Date:10/31/26
The score is held up by a conservatively financed balance sheet and continued positive free cash flow, but is weighed down by a sharp TTM profitability reset (net loss and margin compression) and clearly bearish technical momentum. Valuation is also constrained by negative earnings and a very low dividend yield.
Positive Factors
Low Leverage
Tigermed’s low leverage and sizable equity base provide financial flexibility through changing business conditions. Limited debt obligations should reduce balance-sheet strain, preserve capacity to fund operations, and support investment in clinical research capabilities over the next several quarters.
Negative Factors
TTM Net Loss
The shift from healthy annual profitability to a TTM net loss is a material deterioration in earnings quality. Sustained losses can weaken internal funding capacity, reduce returns to shareholders, and make future performance more dependent on restoring profitability across the business.
Read all positive and negative factors
Positive Factors
Negative Factors
Low Leverage
Tigermed’s low leverage and sizable equity base provide financial flexibility through changing business conditions. Limited debt obligations should reduce balance-sheet strain, preserve capacity to fund operations, and support investment in clinical research capabilities over the next several quarters.
Read all positive factors
Hangzhou Tigermed Consulting Co., Ltd. Class H (3347) vs. iShares MSCI Hong Kong ETF (EWH)
Market Cap
HK$42.54B
Dividend Yield0.38%
Average Volume (3M)1.09M
Price to Earnings (P/E)―
Beta (1Y)1.04
Revenue Growth16.21%
EPS Growth-82.18%
CountryHK
Employees11,130
SectorHealthcare
Sector Strength45
IndustryBiotechnology
Share Statistics
EPS (TTM)-0.64
Shares Outstanding123,124,800
10 Day Avg. Volume1,176,019
30 Day Avg. Volume1,087,638
Financial Highlights & Ratios
PEG Ratio0.31
Price to Book (P/B)1.57
Price to Sales (P/S)4.81
P/FCF Ratio36.40
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price Target
HK$47.68Price Target Upside-11.71% Downside
Rating ConsensusModerate Buy
Number of Analyst Covering4
EPS Forecast (FY)0.59
Revenue Forecast (FY)HK$9.08B
Hangzhou Tigermed Consulting Co., Ltd. Class H Business Overview & Revenue Model
Company Description
Hangzhou Tigermed Consulting Co., Ltd. provides clinical research services for research and development of domestic and foreign pharmaceutical and health related products. Its services include technical services for phase I to phase IV clinical tr...
Hangzhou Tigermed Consulting Co., Ltd. Class H Financial Statement Overview
Summary
Income Statement
52
Neutral
Balance Sheet
76
Positive
Cash Flow
68
Positive
| Breakdown | TTM | Dec 2025 | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 |
|---|---|---|---|---|---|---|
Income Statement | ||||||
| Total Revenue | 7.59B | 6.83B | 6.60B | 7.38B | 7.09B | 5.21B |
| Gross Profit | 1.96B | 1.87B | 2.24B | 2.85B | 2.81B | 2.27B |
| EBITDA | 1.76B | 1.42B | 1.13B | 2.91B | 2.93B | 3.90B |
| Net Income | -270.08M | 887.89M | 405.14M | 2.02B | 2.01B | 2.87B |
Balance Sheet | ||||||
| Total Assets | 27.99B | 28.36B | 28.67B | 29.68B | 27.45B | 23.74B |
| Cash, Cash Equivalents and Short-Term Investments | 2.12B | 1.84B | 2.13B | 7.46B | 7.88B | 8.57B |
| Total Debt | 2.10B | 1.47B | 2.63B | 2.83B | 2.80B | 1.19B |
| Total Liabilities | 4.72B | 4.10B | 4.61B | 5.23B | 4.77B | 3.14B |
| Stockholders Equity | 19.64B | 20.96B | 20.67B | 21.03B | 19.58B | 18.12B |
Cash Flow | ||||||
| Free Cash Flow | 1.12B | 903.72M | 740.45M | 836.68M | 908.90M | 1.06B |
| Operating Cash Flow | 1.29B | 1.12B | 1.10B | 1.15B | 1.36B | 1.42B |
| Investing Cash Flow | -173.45M | 491.56M | -4.74B | -1.53B | -2.79B | -2.78B |
| Financing Cash Flow | -625.76M | -1.93B | -1.70B | -7.81M | 809.25M | -163.09M |
Hangzhou Tigermed Consulting Co., Ltd. Class H Technical Analysis
Negative
54.00
Price Trends
42.17
Negative
39.27
Negative
41.15
Negative
Market Momentum
-1.55
Positive
37.92
Neutral
28.20
Neutral
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For HK:3347, the sentiment is Negative. The current price of 54 is above the 20-day moving average (MA) of 41.57, above the 50-day MA of 42.17, and above the 200-day MA of 41.15, indicating a bearish trend. The MACD of -1.55 indicates Positive momentum. The RSI at 37.92 is Neutral, neither overbought nor oversold. The STOCH value of 28.20 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for HK:3347.
Hangzhou Tigermed Consulting Co., Ltd. Class H Peers Comparison
UnderperformOutperform
Sector (51)
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
75 Outperform | HK$506.60B | 15.47 | 30.77% | 1.29% | 38.26% | 84.56% | |
69 Neutral | HK$84.68B | 46.36 | 14.00% | ― | 41.52% | 17.10% | |
60 Neutral | HK$36.16B | 29.06 | 13.10% | 0.60% | 16.68% | 442.43% | |
55 Neutral | HK$42.54B | -76.42 | -2.00% | 0.38% | 16.21% | -82.18% | |
54 Neutral | HK$1.59B | 50.49 | 4.04% | 2.40% | 169.02% | -24.61% | |
51 Neutral | $7.86B | -0.30 | -43.30% | 2.27% | 22.53% | -2.21% |
* Healthcare Sector Average
HK:3347
Hangzhou Tigermed Consulting Co., Ltd. Class H
37.92
-8.52
-18.35%
HK:2359
WuXi AppTec Co., Ltd. Class H
185.40
83.35
81.67%
HK:6127
JOINN Laboratories (China) Co., Ltd. Class H
22.88
2.30
11.20%
HK:6667
Mega Genomics Limited
7.08
0.05
0.68%
HK:9860
ADICON Holdings Limited
4.50
-2.10
-31.82%
HK:2268
WuXi XDC Cayman, Inc.
66.65
-6.05
-8.32%
Hangzhou Tigermed Consulting Co., Ltd. Class H Corporate Events
Hangzhou Tigermed Publishes Unaudited Q3 2026 Report Under Hong Kong Rules
Oct 29, 2026
Hangzhou Tigermed Consulting Co., Ltd., a Hong Kong-listed clinical research and pharmaceutical services provider, has released its third quarterly report for the 2026 financial year. The Group prepares its financial statements under China Account...
Tigermed Warns Investors as Subsidiary Frontage Faces Trading Halt on Potential Takeover News
Oct 22, 2026
Hangzhou Tigermed Consulting has disclosed that trading in the shares of its Hong Kong-listed subsidiary Frontage Holdings Corporation has been halted pending an announcement under the Code on Takeovers and Mergers that will contain inside informa...
Tigermed Directors Fined Over Shareholding Disclosure Violations in China
Oct 16, 2026
Hangzhou Tigermed Consulting Co., Ltd., a leading Chinese clinical research and biopharmaceutical services group listed in Hong Kong, provides contract research and consulting support to pharmaceutical and biotech firms. Its business depends heavi...
Tigermed Sets Board Meeting to Approve Third-Quarter Results
Oct 16, 2026
Hangzhou Tigermed Consulting Co., Ltd. has scheduled a board meeting for October 29, 2026, to review and approve the group’s third quarterly report for the nine months ended September 30, 2026. The session may also consider additional resolu...
Tigermed Adjusts 2026 Restricted Share Incentive Scheme After Shareholder Approval
Oct 9, 2026
Hangzhou Tigermed Consulting has secured shareholder approval for its 2026 Restricted A Share Incentive Scheme, including related management measures and authorisation for the board to administer the plan. The company also reported that internal i...
Tigermed Shareholders Approve All Resolutions at 2026 Extraordinary Meetings
Sep 23, 2026
Hangzhou Tigermed Consulting Co., Ltd., a PRC-based contract research and clinical trial services provider listed via both A and H shares, held its 2026 third extraordinary general meeting and separate A share and H share class meetings in Hangzho...
Tigermed Directors Face Regulatory Warning and Fines Over Disclosure Lapses
Sep 11, 2026
Hangzhou Tigermed Consulting has disclosed that its directors and controlling shareholders, Mr. Ye Xiaoping and Ms. Cao Xiaochun, have received a formal warning letter from the Zhejiang arm of the China Securities Regulatory Commission for failing...
Tigermed Calls 2026 EGM to Reshape Capital Structure and Launch New Share Incentive Plan
Sep 3, 2026
Hangzhou Tigermed Consulting has called a third extraordinary general meeting for September 23, 2026, in Hangzhou to seek shareholder approval for a wide-ranging package of capital and governance measures. The agenda includes changing the use of p...
Tigermed Calls 2026 H Shareholders’ Meeting to Vote on Capital Reduction and New Buyback Mandate
Sep 3, 2026
Hangzhou Tigermed Consulting has called a third H share class meeting for September 23, 2026 in Hangzhou, to be held after its extraordinary general meeting and A share class meeting, with H shareholders of record on September 18 eligible to atten...
Tigermed Unveils 2026 Restricted A Share Incentive Scheme to Align Talent and Growth
Aug 28, 2026
Tigermed’s board has approved the proposed adoption of a 2026 Restricted A Share Incentive Scheme, accompanying assessment management measures, and authorization for the board to handle related implementation matters, all subject to sharehol...
Tigermed Cancels Remaining Treasury Shares to Cut Registered Capital
Aug 28, 2026
Hangzhou Tigermed Consulting Co., Ltd. has decided to cancel all remaining 5,883,780 A-share treasury shares previously repurchased under its 2024 buyback plan, shifting their intended use from future equity incentive or employee stock ownership s...
Tigermed Board Approves New 2026 Plan for Remaining H Share Proceeds
Aug 28, 2026
Hangzhou Tigermed Consulting Co., Ltd., a Chinese clinical research services provider listed via H shares in Hong Kong, has raised net proceeds of approximately HK$11.8 billion from its H share offering. The company has repeatedly adjusted the dep...
Tigermed Grows Revenue but Swings to Interim Loss on One-Off Items
Aug 28, 2026
Hangzhou Tigermed Consulting reported a 14.1% year-on-year rise in first-half 2026 revenue to RMB3.71 billion, with gross profit up 4.3% to RMB1.02 billion, reflecting continued business expansion in its contract research services. However, the co...
Tigermed Sets August Board Meeting to Approve Interim Results and Weigh Dividend
Aug 18, 2026
Hangzhou Tigermed Consulting Co., Ltd. has scheduled a board meeting for August 28, 2026, to review and approve the unaudited interim results for the six months ended June 30, 2026, and to authorize their public release. The board will also consid...
Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.